1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Malignant pleural mesothelioma (MPM) - Pipeline Insight, 2021

Malignant pleural mesothelioma (MPM) - Pipeline Insight, 2021

  • July 2021
  • 70 pages
  • ID: 6124342
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“Malignant pleural mesothelioma (MPM) - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Malignant pleural mesothelioma (MPM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Malignant pleural mesothelioma (MPM) Understanding

Malignant pleural mesothelioma (MPM): Overview
Malignant pleural mesothelioma is a cancer that develops in the pleura, the thin tissue lining the lungs. Symptoms of pleural mesothelioma include chest pain, coughing and pleural effusion. The cause of pleural mesothelioma is exposure to asbestos fibers, which a person can inhale into the lungs. Diagnosis of malignant pleural mesothelioma includes multiple tests such as an X-ray or CT scan, blood tests, and biopsy to verify a malignant pleural mesothelioma diagnosis. The standard pleural mesothelioma treatment options include surgery, radiation therapy and chemotherapy. Emerging treatments include novel therapies such as immunotherapy, gene therapy and photodynamic therapy to treat pleural mesothelioma.

"Malignant pleural mesothelioma (MPM) - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant pleural mesothelioma (MPM) pipeline landscape is provided which includes the disease overview and Malignant pleural mesothelioma (MPM) treatment guidelines. The assessment part of the report embraces, in depth Malignant pleural mesothelioma (MPM) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malignant pleural mesothelioma (MPM) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Malignant pleural mesothelioma (MPM) R&D. The therapies under development are focused on novel approaches to treat/improve Malignant pleural mesothelioma (MPM).

Malignant pleural mesothelioma (MPM) Emerging Drugs Chapters

This segment of the Malignant pleural mesothelioma (MPM) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Malignant pleural mesothelioma (MPM) Emerging Drugs
• REIC gene therapy: Momotaro-Gene
REIC gene therapy is a novel investigational gene therapy with unique dual mechanisms of action. The drug candidate leverages the company’s proprietary adenoviral vector technology platform to deliver the Reduced Expression in Immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene) into cancer cells, where the expression of the gene has been shown to be markedly downregulated. The resulting increase in REIC/Dkk-3 gene expression in cancer cells triggers immunogenic cell death selectively in cancer cells. The drug is in Phase II clinical studies for the treatment of malignant pleural mesothelioma (MPM).

• ONCOS-102: Targovax
ONCOS-102 is an experimental adenovirus-based cancer therapy. The drug is in Phase II clinical studies for the treatment of malignant pleural mesothelioma (MPM). In January 2015, the US FDA granted orphan drug designation to ONCOS 102 for the treatment of malignant mesothelioma.
Further product details are provided in the report……..

Malignant pleural mesothelioma (MPM): Therapeutic Assessment
This segment of the report provides insights about the different Malignant pleural mesothelioma (MPM) drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Malignant pleural mesothelioma (MPM)
There are approx. 20+ key companies which are developing the therapies for Malignant pleural mesothelioma (MPM). The companies which have their Malignant pleural mesothelioma (MPM) drug candidates in the most advanced stage, i.e. Phase II include, Targovax.

• Phases
This report covers around 20+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Malignant pleural mesothelioma (MPM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malignant pleural mesothelioma (MPM): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Malignant pleural mesothelioma (MPM) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant pleural mesothelioma (MPM) drugs.

Malignant pleural mesothelioma (MPM) Report Insights
• Malignant pleural mesothelioma (MPM) Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Malignant pleural mesothelioma (MPM) Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Malignant pleural mesothelioma (MPM) drugs?
• How many Malignant pleural mesothelioma (MPM) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant pleural mesothelioma (MPM)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Malignant pleural mesothelioma (MPM) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Malignant pleural mesothelioma (MPM) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Momotaro-Gene
• Ys Therapeutics
• MedImmune
• TCR2 Therapeutics
• Atara Biotherapeutics
• Inhibrx
• Eisai
• Targovax
• Merck & Co
• Bayer HealthCare
• SELLAS Life Sciences Group
• CanBas
• Johnson & Johnson
• Sumitomo Dainippon Pharma Oncology
• FKD Therapies
• Virttu Biologics
• MolMed

Key Products
• REIC gene therapy
• YS 110
• Tremelimumab
• TC 210
• ATA 2271
• INBRX 109
• Amatuximab
• ONCOS 102
• Pembrolizumab
• BAY-94-9343
• Galinpepimut S
• CBP 501
• Trabectedin
• Napabucasin
• Nadofaragene firadenovec
• HSV 1716
• NGR-TNF MolMed

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

C-C Chemokine Receptor Type 4 - Drugs In Development, 2021

  • $ 3500
  • July 2021
  • 63 pages

C-C Chemokine Receptor Type 4 - Drugs In Development, 2021 Summary C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 ...

  • World
  • Therapy
  • Lymphoma
  • Industry analysis
  • Health Provider Density

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on